BrightSpring (BTSG) Q4 2025 earnings review
Massive Margin Expansion Driven by Specialty Mix Shift
BrightSpring closed 2025 firing on all cylinders, reporting a 29.3% YoY revenue surge in Q4. However, the real story is profitability: Adjusted EBITDA growth accelerated to 40.7%, significantly outpacing the top line. Management's strategy is clear—they are aggressively shifting the Pharmacy Solutions mix toward high-value Specialty and Infusion Limited Distribution Drugs (LDDs). While raw prescription volumes slightly declined, revenue per script skyrocketed. The balance sheet is also rapidly improving, with leverage compressing from 4.16x to 2.99x in just 12 months. With robust FY26 guidance projecting another ~25% leap in Adjusted EBITDA, the company's growth trajectory is securely intact.
🐂 Bull Case
Gross profit per script jumped 26% YoY to $23.52 in Q4. By focusing on complex care and LDDs, BrightSpring is proving it can extract massive margin expansion without relying entirely on underlying volume growth.
Strong cash flow generation allowed BrightSpring to slash its net leverage ratio from 4.16x at the end of 2024 to 2.99x at the end of 2025, completely shifting the narrative away from debt concerns.
🐻 Bear Case
Despite a 32% revenue surge in Pharmacy Solutions, actual prescriptions dispensed fell 1% YoY in Q4. Relying strictly on price and mix shifts to drive growth carries long-term sustainability risks.
The company just closed on 107 home health and hospice branches from Amedisys/LHC. Integrating this many distinct locations simultaneously introduces significant execution and operational risks.
⚖️ Verdict: 🟢
Bullish. The combination of accelerating EBITDA growth, massive operating cash flow generation, and rapid deleveraging paints the picture of a highly disciplined management team successfully executing a high-margin pivot.
Key Themes
Specialty Pharmacy Mix Shift Powers the Engine
BrightSpring's deliberate pivot toward Specialty and Infusion Limited Distribution Drugs (LDDs) is yielding exceptional results. In Q4, Revenue per script hit an impressive $291.07, up 33% YoY. This mix shift is the primary catalyst behind the company's accelerating EBITDA profile, proving that BrightSpring's core strategy of managing complex populations is highly lucrative.
Provider Services Census is Accelerating
The Provider Services segment is showing robust physical volume growth, contrasting with the pharmacy side. Home Health Care average daily census hit 34,593 in Q4, accelerating to a 15% YoY growth rate (compared to 12% in Q1). Rehab Care persons served also grew 13%. This provides stable, physical demand underlying the broader enterprise.
Flat Script Volumes Contradict the Growth Narrative
A specific data point contradicting the sheer top-line euphoria: Pharmacy Solutions prescriptions dispensed contracted by 1% YoY in Q4 (10.84M vs 10.96M). While management has historically attributed volume weakness to proactive exits of uneconomic contracts, structurally declining volumes require close monitoring. The company cannot rely entirely on drug pricing and mix to sustain 30%+ revenue growth indefinitely.
Amedisys/LHC Integration Execution
The company completed the acquisition of 107 home health and hospice branches from Amedisys/LHC in Q4. While management expects these to contribute ~$30M in Adjusted EBITDA in 2026, onboarding over a hundred branches simultaneously is a heavy operational lift that could distract from organic growth initiatives.
Macro Regulatory Headwinds
As noted in prior quarters, the broader macro environment poses lingering risks. The full implementation of the Inflation Reduction Act (IRA) and continuous pressures on CMS home health rates represent external factors that, while currently being mitigated, could compress future gross margins.
Other KPIs
Reversing spectacularly from previous years. Operating cash flow surged from a mere $24M in FY24 to $490M in FY25. This explosion in cash generation funded acquisitions, share repurchases ($43.2M), and enabled the massive deleveraging sequence.
Management set a goal throughout 2025 to drive leverage down toward the 3.0x mark (pro forma for the Community Living divestiture). They achieved 2.99x organically by year-end, down from 4.16x at the close of 2024, significantly de-risking the equity story.
Guidance
Decelerating. The midpoint of $14.72B implies ~14% YoY growth, a step down from the blistering 28.2% growth achieved in FY25. However, this base is now structurally higher-margin.
Accelerating absolute profitability. The midpoint of $775M implies a 25.4% YoY increase, validating management's ability to maintain high margins. This includes ~$30M from the Amedisys/LHC acquisition.
Accelerating sharply. Implies 26.3% to 29.7% growth compared to FY25. This massive bump is heavily driven by the inorganic addition of the 107 newly acquired Amedisys and LHC branches.
Key Questions
Base Script Volume Trajectory
With Q4 script volumes down 1% YoY despite massive revenue growth, at what point does underlying volume attrition begin to negatively impact procurement scale and manufacturer rebates?
Amedisys Integration Timeline
You are guiding to $30M in Adjusted EBITDA from the Amedisys/LHC acquisition in 2026. What is the margin profile of these acquired assets compared to your legacy home health branches, and when do you expect full synergy realization?
Community Living Divestiture Timing
The Community Living divestiture to Sevita was originally announced in January 2025 and is now expected to close by the end of Q1 2026. Are there any remaining regulatory hurdles, and how will the final net cash proceeds be deployed upon receipt?